BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
+18.58%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$115M
AUM Growth
+$115M
(+6.7%)
Cap. Flow
-$6.39M
Cap. Flow
% of AUM
-5.53%
Top 10 Holdings %
Top 10 Hldgs %
66.83%
Holding
65
New
5
Increased
9
Reduced
7
Closed
4
Top Buys
| 1 |
Acadia Pharmaceuticals
ACAD
|
$2.31M |
| 2 |
EQT Corp
EQT
|
$1.27M |
| 3 |
Castle Biosciences
CSTL
|
$684K |
| 4 |
Alphatec Holdings
ATEC
|
$612K |
| 5 |
KalVista Pharmaceuticals
KALV
|
$417K |
Top Sells
| 1 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$4.27M |
| 2 |
Harrow
HROW
|
$3.47M |
| 3 |
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
|
$1.73M |
| 4 |
Neurocrine Biosciences
NBIX
|
$1.38M |
| 5 |
Elutia
ELUT
|
$878K |
Sector Composition
| 1 | Healthcare | 97.17% |
| 2 | Energy | 2.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Bristol-Myers Squibb
BMY
$96B
| $35.5M | 30.74% | 686,182 -2,036 | -0.3% | -$105K |
|
2
Biodesix
BDSX
$62.6M
| $10.1M | 8.77% | 5,696,113 | – | – |
|
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $6.16M | 5.33% | 400,400 +150,000 | +60% | +$2.31M |
|
|
4
Elutia
ELUT
$96.7M
| $5.03M | 4.36% | 1,321,215 -230,440 | -15% | -$878K |
|
5
United Therapeutics
UTHR
$13.8B
| $3.58M | 3.1% | 10,000 | – | – |
|
6
Prothena Corp
PRTA
$441M
| $3.51M | 3.04% | 209,574 +6,000 | +3% | +$100K |
|
|
7
Neurocrine Biosciences
NBIX
$13.8B
| $3.48M | 3.02% | 30,240 -12,000 | -28% | -$1.38M |
|
8
Corcept Therapeutics
CORT
$7.35B
| $3.42M | 2.97% | 74,000 | – | – |
|
|
9
Harrow
HROW
$1.44B
| $3.28M | 2.84% | 72,910 -77,090 | -51% | -$3.47M |
|
10
QuidelOrtho
QDEL
$1.95B
| $3.08M | 2.67% | 67,619 | – | – |
|
11
Foghorn Therapeutics
FHTX
$286M
| $2.99M | 2.59% | 320,930 | – | – |
|
12
Axogen
AXGN
$743M
| $2.76M | 2.39% | 197,000 | – | – |
|
13
Phreesia
PHR
$1.88B
| $2.61M | 2.26% | 114,700 | – | – |
|
14
Stoke Therapeutics
STOK
$1.08B
| $2.58M | 2.23% | 210,000 | – | – |
|
15
Protagonist Therapeutics
PTGX
$3.67B
| $2.16M | 1.87% | 48,000 | – | – |
|
16
Travere Therapeutics
TVTX
$1.56B
| $2.07M | 1.79% | 148,000 +26,000 | +21% | +$364K |
|
17
Masimo
MASI
$7.59B
| $2.04M | 1.76% | 15,280 | – | – |
|
18
Ovintiv
OVV
$10.8B
| $2M | 1.73% | 52,200 -22,000 | -30% | -$843K |
|
19
DocGo
DCGO
$153M
| $1.71M | 1.48% | 515,000 +55,000 | +12% | +$183K |
|
|
20
Castle Biosciences
CSTL
$696M
| $1.65M | 1.43% | 58,000 +24,000 | +71% | +$684K |
|
21
Alkermes
ALKS
$4.78B
| $1.4M | 1.21% | 50,000 | – | – |
|
|
22
EQT Corp
EQT
$32.4B
| $1.27M | 1.1% | +34,619 | New | +$1.27M |
|
|
23
Alphatec Holdings
ATEC
$2.35B
| $1.1M | 0.95% | 198,000 +110,000 | +125% | +$612K |
|
|
24
KalVista Pharmaceuticals
KALV
$678M
| $950K | 0.82% | 82,000 +36,000 | +78% | +$417K |
|
25
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $750K | 0.65% | 30,000 | – | – |
|